Harbour BioMed and Kelun-Biotech Secure NMPA IND Approval for Atopic Dermatitis Therapy
Event summary
- Harbour BioMed and Kelun-Biotech received NMPA IND approval for HBM7575/SKB575, a bispecific antibody targeting atopic dermatitis.
- The therapy targets TSLP and an undisclosed antigen, aiming for long-acting, durable disease control.
- Kelun-Biotech leads development and commercialization, with Harbour BioMed sharing benefits per their collaboration agreement.
- Preclinical data suggests a human half-life supporting dosing intervals of over three months.
The big picture
The NMPA IND approval for HBM7575/SKB575 underscores the growing focus on innovative therapies for atopic dermatitis, a condition affecting millions worldwide. The collaboration between Harbour BioMed and Kelun-Biotech highlights the strategic importance of bispecific antibodies in targeting complex autoimmune diseases, with potential implications for other inflammatory conditions.
What we're watching
- Clinical Development Pace
- The speed at which HBM7575/SKB575 advances through clinical trials will determine its competitive positioning in the atopic dermatitis market.
- Market Differentiation
- Whether the long-acting profile and dual mechanism of HBM7575/SKB575 can overcome resistance issues and establish it as a best-in-class therapy.
- Commercialization Strategy
- How Kelun-Biotech and Harbour BioMed execute their global development and commercialization plans, particularly in addressing unmet needs in China and beyond.
Related topics